RecruitingPhase 3NCT07332442

Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea


Sponsor

Yale University

Enrollment

250 participants

Start Date

May 18, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The study design is a randomized, controlled clinical trial to test the hypothesis that arousal threshold (ArTH) will affect how individuals with obstructive sleep apnea (OSA, Apnea-Hypopnea Index (AHI) of 10/hour of higher) respond to CPAP therapy regarding adherence and cognitive function (executive function). Investigators hypothesize that raising ArTH with eszopiclone will improve adherence to CPAP and neurocognitive function with CPAP therapy. Investigators also hypothesize that a lower baseline ArTH is associated with worse CPAP adherence, while a higher baseline ArTH is associated with improved neurocognitive outcomes with CPAP therapy.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Eszopiclone and a drug called Placebo for people with obstructive sleep apnea and sleep apnea. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEszopiclone

3mg for \< 65 and 2mg for ≥ 65 years

DRUGPlacebo

Matched placebo


Locations(1)

Yale Centers for Sleep Medicine

North Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07332442


Related Trials